Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q2 2023 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, Aug 11, 2023
Slide 1: Q2 2023 Update
Q2 2023 Update August 11, 2023
Slide 2: Live Presentation and Dial-in Information
Live Presentation Friday, August 11, 2023, 8:30 AM (EDT) Participant Dial-in Information Toll Free: 1-877-407-0784 Toll/International: 1-201-689-8560 OR click the Call me™ link for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=comp
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company’s current views with respect to certain current and future events and financial performance. Forward-looking sta
Slide 4: Company Financials Q2 2023
4 Company Financials Q2 2023 Showing consistent topline growth while managing operating costs. (in millions) Q2 2023 Q2 2022 YoY Revenue $4.7 $3.9 + 20% Gross Profit $3.5 $2.8 + 25% Gross Margin 74% 72% +200bp Operating $2.5* $5.8 -57% Expense Operating Profit $0.9 ($3.0) +130% * Includes $1.3 milli
Slide 5: Adjusted EBITDA Non-GAAP Reconciliation
5 Adjusted EBITDA Non-GAAP Reconciliation (in millions) Q2 2023 Q2 2022 Net (Loss) Income ($7.26) $1.64 Non-GAAP adjustments: Interest Expense 4.38 2.95 Depreciation and Amortization 0.26 0.26 EBITDA ($2.62) $4.85 Change in fair value of derivative liabilities 3.82 (7.86) Release of historical accru
Slide 6: UltraMist Sales Metrics
6 UltraMist Sales Metrics Treatments Consumable Revenue 3 + 25% yoy 48 +12% seq • 526 Active Systems in the Thousands + 14% yoy 47 +7% seq 2.5 field at end Q2* 46 45 • 49 systems were sold in Q2 2 2023 compared to 28 in Q1 44 2023 43 1.5 42 • 14% increase in treatments 1 from Q2 2022 to Q2 2023 41 4
Slide 7: 2023 Q3 Revenue Guidance
7 2023 Q3 Revenue Guidance 3rd Quarter 2023 (estimate. +15 – 25% vs Q3 2022) Break Even Gross Margin Opex $1.8mm/mo 75% $1.4mm/mo Unbounded Upside: 1% market share in US wound market = $450 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: § Approved products protected by strong IP § Strong existing reimbursement with room to impr